Objective: To study the association between estrogen replacement therapy in
postmenopausal women and AD using a case-control design. Background: Studi
es of the effect of estrogen therapy on the risk of AD have been limited an
d have yielded conflicting results. Methods: Case patients were all postmen
opausal women who developed AD in the quinquennium 1980 through 1984 in Roc
hester, MN (n = 222). One control subject from the same population and free
of dementia was matched to each case patient by age (+/-3 years) and lengt
h of enrollment in the records-linkage system (n = 222). Estrogen exposure
was defined as any form of' estrogen (oral, parenteral, topical, suppositor
y) used for at least 6 months after the onset of menopause and before the o
nset of AD (or corresponding year in the matched control subject). Informat
ion on dose and duration of use was abstracted. Consistent with the matched
design, analyses entailed conditional logistic regression. Results: AD pat
ients and control subjects had identical age at menarche (median: 13.0 vers
us 13.0 years) and age at menopause (median: 50.0 versus 50.0 years). The f
requency of estrogen use was higher among control subjects than AD patients
(10% versus 5%; odds ratio = 0.42; 95% confidence interval 0.18 to 0.96; p
= 0.04). There was a significant trend of decreasing odds ratios with incr
easing duration of use. The inverse association between estrogen therapy an
d AD remained significant after adjustment for education and age at menopau
se. Conclusion: These results from a population-based study suggest that es
trogen replacement therapy is associated with a reduced risk of AD in postm
enopausal women.